Álvarez-Córdoba, Mónica, Talaverón-Rey, Marta, Povea-Cabello, Suleva, Cilleros-Holgado, Paula, Gómez-Fernández, David, Piñero-Pérez, Rocío, Reche-López, Diana, Munuera-Cabeza, Manuel, Suárez-Carrillo, Alejandra, Romero-González, Ana, Romero-Domínguez, Jose Manuel, López-Cabrera, Alejandra, Armengol, José Ángel, and Sánchez-Alcázar, José Antonio
The term neurodegeneration with brain iron accumulation (NBIA) brings together a broad set of progressive and disabling neurological genetic disorders in which iron is deposited preferentially in certain areas of the brain. Among NBIA disorders, the most frequent subtype is pantothenate kinase-associated neurodegeneration (PKAN) caused by pathologic variants in the PANK2 gene codifying the enzyme pantothenate kinase 2 (PANK2). To date, there are no effective treatments to stop the progression of these diseases. This review discusses the utility of patient-derived cell models as a valuable tool for the identification of pharmacological or natural compounds for implementing polytarget precision medicine in PKAN. Recently, several studies have described that PKAN patient-derived fibroblasts present the main pathological features associated with the disease including intracellular iron overload. Interestingly, treatment of mutant cell cultures with various supplements such as pantothenate, pantethine, vitamin E, omega 3, α-lipoic acid L-carnitine or thiamine, improved all pathophysiological alterations in PKAN fibroblasts with residual expression of the PANK2 enzyme. The information provided by pharmacological screenings in patient-derived cellular models can help optimize therapeutic strategies in individual PKAN patients. [ABSTRACT FROM AUTHOR]